文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Tunny T J, Klemm S A, Gordon R D

University Department of Medicine, Greenslopes Hospital, Brisbane, Queensland, Australia.

Clin Exp Pharmacol Physiol. 1987 Mar;14(3):221-5. doi: 10.1111/j.1440-1681.1987.tb00379.x.

A significant positive correlation was found between changes in circulating noradrenaline (NA) levels and changes in atrial natriuretic peptide (ANP) levels during NA infusion and clonidine administration. 2. A significant positive correlation was also found between changes in arterial blood pressure and changes in ANP level during infusion of angiotensin II and of NA. 3. Two patients with very high circulating NA levels due to phaeochromocytoma, but receiving alpha- and beta-blockade, did not have clearly elevated ANP. A third not receiving medications and aged 73 years had elevated levels. 4. Atrial natriuretic peptide response to NA and angiotensin II may be mediated by changes in blood pressure levels or increased noradrenergic and angiotensinergic receptor activity in the atria or both. Atrial natriuretic peptide may have a role in blood pressure regulation in both normotensive and hypertensive man.

在输注去甲肾上腺素（NA）和给予可乐定期间，循环中去甲肾上腺素（NA）水平的变化与心房利钠肽（ANP）水平的变化之间存在显著正相关。2. 在输注血管紧张素II和NA期间，动脉血压的变化与ANP水平的变化之间也存在显著正相关。3. 两名因嗜铬细胞瘤而循环中NA水平非常高但接受α和β受体阻滞剂治疗的患者，其ANP并未明显升高。第三名未接受药物治疗且73岁的患者ANP水平升高。4. 心房利钠肽对NA和血管紧张素II的反应可能由血压水平的变化或心房中去甲肾上腺素能和血管紧张素能受体活性增加或两者共同介导。心房利钠肽可能在正常血压和高血压人群的血压调节中起作用。

Tunny T J, Klemm S A, Gordon R D

University Department of Medicine, Greenslopes Hospital, Brisbane, Queensland, Australia.

Clin Exp Pharmacol Physiol. 1987 Mar;14(3):221-5. doi: 10.1111/j.1440-1681.1987.tb00379.x.

A significant positive correlation was found between changes in circulating noradrenaline (NA) levels and changes in atrial natriuretic peptide (ANP) levels during NA infusion and clonidine administration. 2. A significant positive correlation was also found between changes in arterial blood pressure and changes in ANP level during infusion of angiotensin II and of NA. 3. Two patients with very high circulating NA levels due to phaeochromocytoma, but receiving alpha- and beta-blockade, did not have clearly elevated ANP. A third not receiving medications and aged 73 years had elevated levels. 4. Atrial natriuretic peptide response to NA and angiotensin II may be mediated by changes in blood pressure levels or increased noradrenergic and angiotensinergic receptor activity in the atria or both. Atrial natriuretic peptide may have a role in blood pressure regulation in both normotensive and hypertensive man.

在输注去甲肾上腺素（NA）和给予可乐定期间，循环中去甲肾上腺素（NA）水平的变化与心房利钠肽（ANP）水平的变化之间存在显著正相关。2. 在输注血管紧张素II和NA期间，动脉血压的变化与ANP水平的变化之间也存在显著正相关。3. 两名因嗜铬细胞瘤而循环中NA水平非常高但接受α和β受体阻滞剂治疗的患者，其ANP并未明显升高。第三名未接受药物治疗且73岁的患者ANP水平升高。4. 心房利钠肽对NA和血管紧张素II的反应可能由血压水平的变化或心房中去甲肾上腺素能和血管紧张素能受体活性增加或两者共同介导。心房利钠肽可能在正常血压和高血压人群的血压调节中起作用。